{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:44:48Z","timestamp":1792727088794,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00381-025-06864-8","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T22:21:28Z","timestamp":1748989288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sustained response to trametinib in an adult patient with neurofibromatosis type 1 and high-grade glioma"],"prefix":"10.1007","volume":"41","author":[{"given":"Bertrand","family":"Dion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayanthen","family":"Sathyakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallie","family":"Coltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Legault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Perreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myreille","family":"D\u2019Astous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lessard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Saikali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Dion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Lava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bouffet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Jabado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Renzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"6864_CR1","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ (2017) Neurofibromatosis type 1. Nat Rev Dis Primers 3:17004. https:\/\/doi.org\/10.1038\/nrdp.2017.4","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"6864_CR2","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s00431-024-05540-4","volume":"183","author":"S Sathyakumar","year":"2024","unstructured":"Sathyakumar S, Martinez M, Perreault S, Legault G, Bouffet E, Jabado N, Larouche V, Renzi S (2024) Advances in pediatric gliomas: from molecular characterization to personalized treatments. Eur J Pediatr 183(6):2549\u20132562. https:\/\/doi.org\/10.1007\/s00431-024-05540-4","journal-title":"Eur J Pediatr"},{"issue":"9","key":"6864_CR3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.2014.58.3922","volume":"33","author":"M Mistry","year":"2015","unstructured":"Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, Stavropoulos J, Alon N, Pole JD, Ray PN, Navickiene V, Mangerel J, Remke M, Buczkowicz P, Ramaswamy V, Guerreiro Stucklin A, Li M, Young EJ, Zhang C, Castelo-Branco P, Tabori U et al (2015) BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol\u202f: Off J Am Soc Clin Oncol 33(9):1015\u20131022. https:\/\/doi.org\/10.1200\/JCO.2014.58.3922","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"2","key":"6864_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3174\/ajnr.A5888","volume":"40","author":"CD Spyris","year":"2019","unstructured":"Spyris CD, Castellino RC, Schniederjan MJ, Kadom N (2019) High-grade gliomas in children with neurofibromatosis type 1: literature review and illustrative cases. AJNR Am J Neuroradiol 40(2):366\u2013369. https:\/\/doi.org\/10.3174\/ajnr.A5888","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"6864_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","volume":"25","author":"F D\u2019Angelo","year":"2019","unstructured":"D\u2019Angelo F, Ceccarelli M, Tala GL, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Iavarone A et al (2019) The molecular landscape of glioma in patients with neurofibromatosis 1. Nat Med 25(1):176\u2013187. https:\/\/doi.org\/10.1038\/s41591-018-0263-8","journal-title":"Nat Med"},{"issue":"6","key":"6864_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/neuonc\/noaa036","volume":"22","author":"RJ Packer","year":"2020","unstructured":"Packer RJ, Iavarone A, Jones DTW, Blakeley JO, Bouffet E, Fisher MJ, Hwang E, Hawkins C, Kilburn L, MacDonald T, Pfister SM, Rood B, Rodriguez FJ, Tabori U, Ramaswamy V, Zhu Y, Fangusaro J, Johnston SA, Gutmann DH (2020) Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro Oncol 22(6):773\u2013784. https:\/\/doi.org\/10.1093\/neuonc\/noaa036","journal-title":"Neuro Oncol"},{"issue":"5","key":"6864_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1212\/wnl.59.5.759","volume":"59","author":"DH Gutmann","year":"2002","unstructured":"Gutmann DH, Rasmussen SA, Wolkenstein P, MacCollin MM, Guha A, Inskip PD, North KN, Poyhonen M, Birch PH, Friedman JM (2002) Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 59(5):759\u2013761. https:\/\/doi.org\/10.1212\/wnl.59.5.759","journal-title":"Neurology"},{"key":"6864_CR8","doi-asserted-by":"publisher","first-page":"101818","DOI":"10.1016\/j.eclinm.2022.101818","volume":"56","author":"C Carton","year":"2023","unstructured":"Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, Salvador H, Azizi AA, Mautner V, R\u00f6hl C, Peltonen S, Stivaros S, Legius E, Oostenbrink R, ERN GENTURIS NF1 Tumour Management Guideline Group (2023) ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine 56:101818. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101818","journal-title":"EClinicalMedicine"},{"issue":"8","key":"6864_CR9","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00415-014-7292-0","volume":"261","author":"BJ Theeler","year":"2014","unstructured":"Theeler BJ, Ellezam B, Yust-Katz S, Slopis JM, Loghin ME, de Groot JF (2014) Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab. J Neurol 261(8):1559\u20131564. https:\/\/doi.org\/10.1007\/s00415-014-7292-0","journal-title":"J Neurol"},{"issue":"7","key":"6864_CR10","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/pbc.22462","volume":"54","author":"AJ Huttner","year":"2010","unstructured":"Huttner AJ, Kieran MW, Yao X, Cruz L, Ladner J, Quayle K, Goumnerova LC, Irons MB, Ullrich NJ (2010) Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer 54(7):890\u2013896. https:\/\/doi.org\/10.1002\/pbc.22462","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"6864_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00401-022-02513-5","volume":"145","author":"PJ Cimino","year":"2023","unstructured":"Cimino PJ, Ketchum C, Turakulov R, Singh O, Abdullaev Z, Giannini C, Pytel P, Lopez GY, Colman H, Nasrallah MP, Santi M, Fernandes IL, Nirschl J, Dahiya S, Neill S, Solomon D, Perez E, Capper D, Mani H, Caccamo D, Aldape K et al (2023) Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1. Acta Neuropathol 145(1):71\u201382. https:\/\/doi.org\/10.1007\/s00401-022-02513-5","journal-title":"Acta Neuropathol"},{"issue":"8","key":"6864_CR12","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"6864_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41582-022-00679-w","volume":"18","author":"C Horbinski","year":"2022","unstructured":"Horbinski C, Berger T, Packer RJ et al (2022) Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat Rev Neurol 18:515\u2013529. https:\/\/doi.org\/10.1038\/s41582-022-00679-w","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"6864_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000529507","volume":"58","author":"C Kotch","year":"2023","unstructured":"Kotch C, Brosius SN, De Raedt T, Fisher MJ (2023) Updates in the management of central and peripheral nervous system tumors among patients with neurofibromatosis type 1 and neurofibromatosis type 2. Pediatr Neurosurg 58(5):267\u2013280. https:\/\/doi.org\/10.1159\/000529507","journal-title":"Pediatr Neurosurg"},{"issue":"2","key":"6864_CR15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1159\/000509773","volume":"13","author":"G Awada","year":"2020","unstructured":"Awada G, Serruys D, Schwarze JK, Van De Voorde L, Duerinck J, Neyns B (2020) Durable complete response of a recurrent mesencephalic glioblastoma treated with trametinib and low-dose dabrafenib in a patient with neurofibromatosis type 1. Case reports in oncology 13(2):1031\u20131036. https:\/\/doi.org\/10.1159\/000509773","journal-title":"Case reports in oncology"},{"key":"6864_CR16","doi-asserted-by":"publisher","first-page":"1254955","DOI":"10.3389\/fmed.2023.1254955","volume":"10","author":"P Ghanem","year":"2023","unstructured":"Ghanem P, Fatteh M, Kamson DO, Balan A, Chang M, Tao J, Blakeley J, Investigators JHMTB, Canzoniero J, Grossman SA, Marrone K, Schreck KC, Anagnostou V (2023) Druggable genomic landscapes of high-grade gliomas. Front Med 10:1254955. https:\/\/doi.org\/10.3389\/fmed.2023.1254955","journal-title":"Front Med"},{"issue":"8","key":"6864_CR17","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/neuonc\/noad033","volume":"25","author":"CG Romo","year":"2023","unstructured":"Romo CG, Piotrowski AF, Campian JL, Diarte J, Rodriguez FJ, Bale TA, Dahiya S, Gutmann DH, Lucas CG, Prichett L, Mellinghoff I, Blakeley JO (2023) Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1. Neuro Oncol 25(8):1474\u20131486. https:\/\/doi.org\/10.1093\/neuonc\/noad033","journal-title":"Neuro Oncol"},{"issue":"2","key":"6864_CR18","doi-asserted-by":"publisher","first-page":"e0277305","DOI":"10.1371\/journal.pone.0277305","volume":"18","author":"J Dougherty","year":"2023","unstructured":"Dougherty J, Harvey K, Liou A, Labella K, Moran D, Brosius S, De Raedt T (2023) Identification of therapeutic sensitivities in a spheroid drug combination screen of neurofibromatosis type I associated high grade gliomas. PLoS ONE 18(2):e0277305. https:\/\/doi.org\/10.1371\/journal.pone.0277305","journal-title":"PLoS ONE"},{"issue":"6","key":"6864_CR19","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1158\/2159-8290.CD-20-1050","volume":"11","author":"BB Campbell","year":"2021","unstructured":"Campbell BB, Galati MA, Stone SC, Riemenschneider AN, Edwards M, Sudhaman S, Siddaway R, Komosa M, Nunes NM, Nobre L, Morrissy AS, Zatzman M, Zapotocky M, Joksimovic L, Kalimuthu SN, Samuel D, Mason G, Bouffet E, Morgenstern DA, Aronson M, Tabori U et al (2021) Mutations in the RAS\/MAPK pathway drive replication repair-deficient hypermutated tumors and confer sensitivity to MEK inhibition. Cancer Discov 11(6):1454\u20131467. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1050","journal-title":"Cancer Discov"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-025-06864-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-025-06864-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-025-06864-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:17:54Z","timestamp":1770815874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-025-06864-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["6864"],"URL":"https:\/\/doi.org\/10.1007\/s00381-025-06864-8","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"202"}}